224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016

Neuromuscular Disorders

Volumn 28, Issue 1, 2018, Pages 87-99

  Allenbach, Yves ^a,d   Mammen, Andrew L ^b   Benveniste, Olivier ^a,d   Stenzel, Werner ^c   Amato, Anthony ^d   Aussey, Audrey ^d   De Bleecker, Jan ^d   de Groot, Ingrid ^d   de Visser, Marianne ^d   Goebel, Hans ^d   Hervier, Baptiste ^d   Fischer, Norina ^d   Hilton Jones, David ^e   Lamb, Janice ^f   Lundberg, Ingrid ^d   Mammen, Andrew ^d   Mozaffar, Tahseen ^d   Nishino, Ichizo ^d   Pestronk, Alan ^d   Schara, Ulrike ^d   Stenzelr, Werner ^d   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NONE   (Germany)

^e Oxford   (United Kingdom)

^f Altair Engineering UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TOXIN; BIOLOGICAL MARKER;

CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE CLASSIFICATION; EPIGENETICS; GENE; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; MAINTENANCE THERAPY; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SEROLOGY; ANIMAL; BLOOD; CLASSIFICATION; IMMUNOPATHOLOGY; MUSCLE DISEASE; NECROSIS; NETHERLANDS; PATHOLOGY;

ANIMALS; BIOMARKERS; HUMANS; IMMUNE SYSTEM DISEASES; MUSCULAR DISEASES; NECROSIS; NETHERLANDS;

EID: 85037040032     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2017.09.016     Document Type: Conference Paper

References (57)

1. Pinal-Fernandez, I., Mammen, A.L., Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol 28 (2016), 619–624.
2. Suzuki, S., Nishikawa, A., Kuwana, M., Nishimura, H., Watanabe, Y., Nakahara, J., et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis, 10, 2015, 61.
3. Suzuki, S., Satoh, T., Sato, S., Otomo, M., Hirayama, Y., Sato, H., et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology 47 (2008), 1539–1542.
4. Suzuki, S., Hayashi, Y.K., Kuwana, M., Tsuburaya, R., Suzuki, N., Nishino, I., Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol 69 (2012), 728–732.
5. Targoff, I.N., Johnson, A.E., Miller, F.W., Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33 (1990), 1361–1370.
6. Watanabe, Y., Uruha, A., Suzuki, S., Nakahara, J., Hamanaka, K., Takayama, K., et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87 (2016), 1038–1044.
7. Benveniste, O., Drouot, L., Jouen, F., Charuel, J.L., Bloch-Queyrat, C., Behin, A., et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63 (2011), 1961–1971.
8. Allenbach, Y., Keraen, J., Bouvier, A.M., Jooste, V., Champtiaux, N., Hervier, B., et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139 (2016), 2131–2135.
9. Pinal-Fernandez, I., Casal-Dominguez, M., Carrino, J.A., Lahouti, A.H., Basharat, P., Albayda, J., et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 76 (2017), 681–687.
10. Needham, M., Fabian, V., Knezevic, W., Panegyres, P., Zilko, P., Mastaglia, F.L., Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 17 (2007), 194–200.
11. Grable-Esposito, P., Katzberg, H.D., Greenberg, S.A., Srinivasan, J., Katz, J., Amato, A.A., Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41 (2010), 185–190.
12. Christopher-Stine, L., Casciola-Rosen, L.A., Hong, G., Chung, T., Corse, A.M., Mammen, A.L., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62 (2010), 2757–2766.
13. Mammen, A.L., Chung, T., Christopher-Stine, L., Rosen, P., Rosen, A., Doering, K.R., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63 (2011), 713–721.
14. Werner, J.L., Christopher-Stine, L., Ghazarian, S.R., Pak, K.S., Kus, J.E., Daya, N.R., et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 64 (2012), 4087–4093.
15. Allenbach, Y., Drouot, L., Rigolet, A., Charuel, J.L., Jouen, F., Romero, N.B., et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 93 (2014), 150–157.
16. Ge, Y., Lu, X., Peng, Q., Shu, X., Wang, G., Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS ONE, 10, 2015 e0141616.
17. Musset, L., Allenbach, Y., Benveniste, O., Boyer, O., Bossuyt, X., Bentow, C., et al. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev 15 (2016), 983–993.
18. Kadoya, M., Hida, A., Hashimoto Maeda, M., Taira, K., Ikenaga, C., Uchio, N., et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm, 3, 2016, e290.
19. Limaye, V., Bundell, C., Hollingsworth, P., Rojana-Udomsart, A., Mastaglia, F., Blumbergs, P., et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52 (2015), 196–203.
20. Tsujikawa, K., Hara, K., Muro, Y., Nakanishi, H., Niwa, Y., Koike, M., et al. HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma. Neurology 87 (2016), 841–843.
21. Troyanov, Y., Targoff, I.N., Tremblay, J.L., Goulet, J.R., Raymond, Y., Senecal, J.L., Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84 (2005), 231–249.
22. Zahr, Z.A., Baer, A.N., Malignancy in myositis. Curr Rheumatol Rep 13 (2011), 208–215.
23. Wang, L., Liu, L., Hao, H., Gao, F., Liu, X., Wang, Z., et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 24 (2014), 335–341.
24. Smith, B., Skeletal muscle necrosis associated with carcinoma. J Pathol 97 (1969), 207–210.
25. Levin, M.I., Mozaffar, T., Al-Lozi, M.T., Pestronk, A., Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50 (1998), 764–767.
26. Reeves, W.H., Nigam, S.K., Blobel, G., Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA 83 (1986), 9507–9511.
27. Hoogendijk, J.E., Amato, A.A., Lecky, B.R., Choy, E.H., Lundberg, I.E., Rose, M.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14 (2004), 337–345.
28. Tiniakou, E., Mammen, A.L., Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 52 (2017), 20–33.
29. Allenbach, Y., Benveniste, O., Goebel, H.H., Stenzel, W., Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol 43 (2017), 62–81.
30. Emslie-Smith, A.M., Engel, A.G., Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 41 (1991), 936–939.
31. Pinal-Fernandez, I., Casciola-Rosen, L.A., Christopher-Stine, L., Corse, A.M., Mammen, A.L., The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42 (2015), 1448–1454.
32. Chung, T., Christopher-Stine, L., Paik, J.J., Corse, A., Mammen, A.L., The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 52 (2015), 189–195.
33. Pestronk, A., Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 23 (2011), 595–604.
34. Miller, T., Al-Lozi, M.T., Lopate, G., Pestronk, A., Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73 (2002), 420–428.
35. Pestronk, A., Kos, K., Lopate, G., Al-Lozi, M.T., Brachio-cervical inflammatory myopathies: clinical, immune, and myopathologic features. Arthritis Rheum 54 (2006), 1687–1696.
36. Noguchi, E., Uruha, A., Suzuki, S., Hamanaka, K., Ohnuki, Y., Tsugawa, J., et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol 74 (2017), 992–999.
37. Basharat, P., Lahouti, A.H., Paik, J.J., Albayda, J., Pinal-Fernandez, I., Bichile, T., et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol 68 (2016), 234–235.
38. Brink, M., Hansson, M., Mathsson, L., Jakobsson, P.J., Holmdahl, R., Hallmans, G., et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 65 (2013), 899–910.
39. Klareskog, L., Stolt, P., Lundberg, K., Kallberg, H., Bengtsson, C., Grunewald, J., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54 (2006), 38–46.
40. de Hair, M.J., Landewe, R.B., van de Sande, M.G., van Schaardenburg, D., van Baarsen, L.G., Gerlag, D.M., et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1654–1658.
41. Mankia, K., Emery, P., Preclinical rheumatoid arthritis: progress toward prevention. Arthritis Rheumatol 68 (2016), 779–788.
42. Klareskog, L., Catrina, A.I., Paget, S., Rheumatoid arthritis. Lancet 373 (2009), 659–672.
43. Chinoy, H., Adimulam, S., Marriage, F., New, P., Vincze, M., Zilahi, E., et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis 71 (2012), 961–965.
44. Mammen, A.L., Pak, K., Williams, E.K., Brisson, D., Coresh, J., Selvin, E., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 64 (2012), 269–272.
45. Arouche-Delaperche, L., Allenbach, Y., Amelin, D., Preusse, C., Mouly, V., Mauhin, W., et al. Pathogenic role of anti-SRP and anti-HMGCR antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol 81 (2017), 538–548.
46. Betteridge, Z., McHugh, N., Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280 (2016), 8–23.
47. Jia, X., Han, B., Onengut-Gumuscu, S., Chen, W.M., Concannon, P.J., Rich, S.S., et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE, 8, 2013 e64683.
48. Rothwell, S., Cooper, R.G., Lundberg, I.E., Miller, F.W., Gregersen, P.K., Bowes, J., et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis 75 (2016), 1558–1566.
49. Candore, G., Lio, D., Colonna Romano, G., Caruso, C., Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 1 (2002), 29–35.
50. Mammen, A.L., Gaudet, D., Brisson, D., Christopher-Stine, L., Lloyd, T.E., Leffell, M.S., et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 64 (2012), 1233–1237.
51. Group, S.C., Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359 (2008), 789–799.
52. Kassardjian, C.D., Lennon, V.A., Alfugham, N.B., Mahler, M., Milone, M., Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 72 (2015), 996–1003.
53. Ramanathan, S., Langguth, D., Hardy, T.A., Garg, N., Bundell, C., Rojana-Udomsart, A., et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e96.
54. Mammen, A.L., Tiniakou, E., Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med 373 (2015), 1680–1682.
55. Valiyil, R., Casciola-Rosen, L., Hong, G., Mammen, A., Christopher-Stine, L., Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 62 (2010), 1328–1334.
56. Condon, M.B., Ashby, D., Pepper, R.J., Cook, H.T., Levy, J.B., Griffith, M., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72 (2013), 1280–1286.
57. Tiniakou, E., Pinal-Fernandez, I., Lloyd, T.E., Albayda, J., Paik, J., Werner, J.L., et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology 56 (2017), 787–794.